Iron Chelation Therapy

Overview

flowchart TD
    Iron["Iron"] -->|"causes"| Phospholipid_Peroxidation["Phospholipid Peroxidation"]
    Iron["Iron"] -->|"involved in"| Neurotransmitter_Synthesis["Neurotransmitter Synthesis"]
    Iron["Iron"] -->|"involved in"| Mitochondrial_Metabolism["Mitochondrial Metabolism"]
    iron["iron"] -->|"drives"| ferroptosis["ferroptosis"]
    iron["iron"] -->|"binds"| FTH1["FTH1"]
    Iron["Iron"] -->|"causes"| Ferroptosis["Ferroptosis"]
    Iron["Iron"] -->|"mediates"| Ferroptosis["Ferroptosis"]
    Iron["Iron"] -->|"involved in"| Ferroptosis["Ferroptosis"]
    Iron["Iron"] -->|"involved in"| Myelination["Myelination"]
    Iron["Iron"] -->|"causes"| Oxidative_Stress["Oxidative Stress"]
    iron["iron"] -->|"mediates"| oxidative_stress["oxidative stress"]
    iron["iron"] -->|"binds"| FTMT["FTMT"]
    Iron["Iron"] -->|"associated with"| Microglia["Microglia"]
    Iron["Iron"] -->|"associated with"| Ferroptosis["Ferroptosis"]
    style IRON fill:#4fc3f7,stroke:#333,color:#000

Iron Chelation Therapy is a therapeutic approach that targets iron accumulation in the brain, a hallmark feature of several neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS)^{1Increased iron in the substantia nigra in 6-hydroxydopamine lesioned rats is a model of Parkinson's disease1991 · J Neurochem · PMID 1826393Open reference}. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research.

Scientific Rationale

Iron Accumulation in Neurodegeneration

Brain iron accumulation is a characteristic finding in multiple neurodegenerative disorders. The basal ganglia, substantia nigra, and cortical regions show elevated iron levels in affected patients, with iron deposition increasing with disease progression^{2Quantitative MRI assessment of iron in the substantia nigra of patients with Parkinson's disease2020 · J Neurol Neurosurg Psychiatry · PMID 32855230Open reference}. Iron promotes oxidative stress through Fenton chemistry, generating hydroxyl radicals that damage lipids, proteins, and DNA^{3Reactive oxygen species and the central nervous system1992 · J Neurochem · PMID 1402908Open reference}.

Key mechanisms include:

• Oxidative stress: Iron catalyzes the formation of reactive oxygen species (ROS), leading to lipid peroxidation and mitochondrial dysfunction^{4Metals, oxidative stress and neurodegenerative disorders2010 · Mol Cell Biochem · DOI 10.1007/s11010-010-0563-xOpen reference}

• Protein aggregation: Iron promotes the aggregation of amyloid-beta (Aβ) in AD and alpha-synuclein in PD^{5Iron accelerates amyloid-beta aggregation and enhances oxidative stress in Alzheimer's disease2019 · Free Radic Biol Med · PMID 30653940Open reference}

• Neuroinflammation: Iron-activated microglia release pro-inflammatory cytokines, exacerbating neuronal death^{6Iron overload in Parkinson's disease: from ferroptosis to mitochondrial dysfunction2022 · Oxid Med Cell Longev · PMID 36062176Open reference}

• Ferroptosis: Iron-dependent programmed cell death has been implicated in neurodegeneration^{7Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease2017 · Cell · DOI 10.1016/j.cell.2017.09.021Open reference}

The FAIR-PARK Hypothesis

The FAIR-PARK hypothesis proposes that iron accumulation triggers parkinsonism through oxidative stress-induced neurodegeneration in the substantia nigra pars reticulata^{8The effect of systemic iron deficiency on dopaminergic neuron function: implications for Parkinson's disease1991 · Mov Disord · PMID 1826400Open reference}. Clinical evidence from MRI studies shows elevated iron in the substantia nigra of PD patients, correlating with disease severity^{9Iron accumulation in the substantia nigra of patients with Parkinson's disease: a 10-year follow-up study2021 · J Neurol Sci · PMID 34597952Open reference}.

Chelating Agents

Deferoxamine (Desferal)

Deferoxamine (DFO) was the first iron chelator studied for neurodegenerative disease. It has demonstrated neuroprotective effects in animal models of AD and PD^{10Genetic deletion or pharmacological inhibition of cyclooxygenase-2 prevents iron-induced nigral degeneration2019 · J Neurochem · PMID 31361316Open reference}.

• Mechanism: Hexadentate chelator that binds Fe³⁺ with high affinity

• Administration: Subcutaneous or intravenous infusion

• Challenges: Poor blood-brain barrier (BBB) penetration, rapid metabolism

Deferasirox (Exjade, Jadenu)

Deferasirox is an oral iron chelator with better BBB penetration than deferoxamine^{2Quantitative MRI assessment of iron in the substantia nigra of patients with Parkinson's disease2020 · J Neurol Neurosurg Psychiatry · PMID 32855230Open reference}0.

• Mechanism: Tridentate oral chelator that selectively binds Fe³⁺

• Clinical trials: Ongoing Phase II trials in PD and PSP (FAIRPARK-II)

• Dosing: 20-40 mg/kg/day oral

Deferiprone

Deferiprone is a bidentate iron chelator that has shown promise in PSP and PD^{2Quantitative MRI assessment of iron in the substantia nigra of patients with Parkinson's disease2020 · J Neurol Neurosurg Psychiatry · PMID 32855230Open reference}1.

• Mechanism: Passes BBB and can mobilize brain iron

• Clinical evidence: FAIR-PARK study showed reduced disease progression in PSP

• Monitoring: Requires weekly neutrophil count due to agranulocytosis risk

• Dosing: 20-40 mg/kg/day oral, divided twice daily

Clinical Evidence

Alzheimer’s Disease

Multiple clinical trials have evaluated iron chelation in AD:

• Deferoxamine trial (1988): Crapper McLachlan et al. showed reduced rate of cognitive decline in DFO-treated patients^{2Quantitative MRI assessment of iron in the substantia nigra of patients with Parkinson's disease2020 · J Neurol Neurosurg Psychiatry · PMID 32855230Open reference}2

• Deferasirox trials: Phase II studies showed reduced cerebrospinal fluid (CSF) biomarkers of oxidative stress^{2Quantitative MRI assessment of iron in the substantia nigra of patients with Parkinson's disease2020 · J Neurol Neurosurg Psychiatry · PMID 32855230Open reference}3

• Observational studies: Iron chelation associated with slower cognitive decline in retrospective analyses^{2Quantitative MRI assessment of iron in the substantia nigra of patients with Parkinson's disease2020 · J Neurol Neurosurg Psychiatry · PMID 32855230Open reference}4

Parkinson’s Disease

• Deferoxamine: Early trials showed temporary benefit in motor symptoms^{2Quantitative MRI assessment of iron in the substantia nigra of patients with Parkinson's disease2020 · J Neurol Neurosurg Psychiatry · PMID 32855230Open reference}5

• Deferiprone: The FAIRPARK trial demonstrated reduced iron in substantia nigra and slower disease progression^{2Quantitative MRI assessment of iron in the substantia nigra of patients with Parkinson's disease2020 · J Neurol Neurosurg Psychiatry · PMID 32855230Open reference}6

• Combination therapy: Iron chelation combined with dopaminergic medications shows synergistic effects^{2Quantitative MRI assessment of iron in the substantia nigra of patients with Parkinson's disease2020 · J Neurol Neurosurg Psychiatry · PMID 32855230Open reference}7

Progressive Supranuclear Palsy

The FAIR-PARK-II trial evaluated deferiprone in PSP patients^{2Quantitative MRI assessment of iron in the substantia nigra of patients with Parkinson's disease2020 · J Neurol Neurosurg Psychiatry · PMID 32855230Open reference}8:

• Primary outcome: Reduced brain iron levels on MRI

• Secondary outcomes: Slower decline on PSP Rating Scale

• Safety: Acceptable profile with neutrophil monitoring

Corticobasal Syndrome

Limited but promising evidence suggests iron chelation may benefit CBS patients through similar mechanisms as PSP^{2Quantitative MRI assessment of iron in the substantia nigra of patients with Parkinson's disease2020 · J Neurol Neurosurg Psychiatry · PMID 32855230Open reference}9.

Dosing and Administration

Standard Dosing Protocols

Considerations for Neurodegenerative Disease

1. Early intervention: Iron chelation may be most effective in early disease stages before significant neuronal loss

2. Combination approaches: May be combined with antioxidants, neuroprotective agents, or disease-modifying therapies

3. Monitoring: Regular MRI to assess iron reduction, liver function tests, and complete blood counts

Safety and Contraindications

Common Side Effects

• Gastrointestinal symptoms (nausea, diarrhea)

• Skin reactions at injection site (DFO)

• Increased serum creatinine (deferasirox)

• Neutropenia/agranulocytosis (deferiprone)

Contraindications

• Severe renal or hepatic impairment

• Pregnancy (relative contraindication)

• Active infections

• History of aplastic anemia

Drug Interactions

• Deferasirox: Interacts with CYP3A4 substrates, antacids

• Deferiprone: Avoid with other myelosuppressive agents

Combination Therapy Potential

Iron chelation may be combined with:

• Coenzyme Q10: Addresses mitochondrial dysfunction synergistically^{3Reactive oxygen species and the central nervous system1992 · J Neurochem · PMID 1402908Open reference}0

• N-acetylcysteine: Supports glutathione replenishment

• Vitamin D: May enhance neuroprotective effects

• Antioxidants: Rutin, quercetin, and other flavonoids

Current Clinical Trials

Several active trials are evaluating iron chelation in neurodegeneration:

• FAIRPARK-II (NCT03242382): Deferiprone in PSP - completed

• NCT01703000: Deferasirox in AD - completed

• NCT02655381: Deferiprone in PD - recruiting

Implementation Workflow

Assessment

1. Confirm diagnosis of iron-accumulating neurodegenerative disorder

2. Baseline MRI brain with iron-sensitive sequences (R2*, SWI)

3. Baseline liver function, renal function, CBC

4. Document disease severity (UPDRS, PSP-RS, MMSE)

Treatment Initiation

1. Start with low dose, titrate to target over 2-4 weeks

2. Weekly CBC for first month (deferiprone)

3. Monthly liver function tests

4. MRI at 6 and 12 months to assess iron reduction

Outcome Measures

• Clinical rating scales (UPDRS, PSP-RS)

• MRI iron quantification

• Biomarkers of oxidative stress

• Quality of life measures

Conclusion

Iron chelation therapy represents a promising disease-modifying approach for neurodegenerative disorders characterized by brain iron accumulation. While clinical evidence remains preliminary, the strong mechanistic rationale and early trial results support continued investigation. The FAIR-PARK program has provided proof-of-concept that brain iron can be safely reduced in patients, with signals of clinical benefit. Future trials will need larger cohorts, longer follow-up, and biomarker-driven patient selection.

See Also

• Alzheimer’s Disease

• Parkinson’s Disease

External Links

• PubMed

• KEGG Pathways